Work

A phase 1b/2 study of the combination of the IDO pathway inhibitor indoximod and temozolomide for adult patients with temozolomide-refractory primary malignant brain tumors: Safety analysis and preliminary efficacy of the phase 1b component.

Year: 2015

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2015.33.15_suppl.2070

Authors: Howard Colman, Frank Mott, Alexander I. Spira, Theodore S. Johnson, Yousef Zakharia, Nicholas N. Vahanian, Charles J. Link, Eugene Paul Kennedy, Ramses F. Sadek, David Munn, Olivier Rixe

Institutions: University of Utah, Huntsman Cancer Institute, Augusta University, Georgia Regents Medical Center, Virginia Cancer Specialists, University of Iowa Hospitals and Clinics, NewLink Genetics (United States), UNM Comprehensive Cancer Center

Language: English

Topic: Glioma Diagnosis and Treatment

Subfield: Genetics (clinical)

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2602385701

Cites:

Cited by: 13

Related to: 10